• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    2/10/23 3:03:40 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBY alert in real time by email
    SC 13G/A 1 nby_13ga.htm NBY 13GA

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    NovaBay Pharmaceuticals, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    66987P300

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Hudson Bay Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    225,909 shares of Common Stock issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock* (see Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    225,909 shares of Common Stock issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock* (see Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    225,909 shares of Common Stock issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock* (see Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%* (see Item 4)

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * As more fully described in Item 4, these shares of Common Stock are issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock, which are each subject to a 9.99% beneficial ownership blocker and the percentage set forth on row (11) and the number of shares of Common Stock set forth on rows (6), (8) and (9) give effect to such blocker.

     
     

     

    1

    NAME OF REPORTING PERSON

    Sander Gerber

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    225,909 shares of Common Stock issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock* (see Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    225,909 shares of Common Stock issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock* (see Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    225,909 shares of Common Stock issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock* (see Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%* (see Item 4)

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, these shares of Common Stock are issuable upon exercise of warrants and/or conversion of shares of convertible preferred stock, which are each subject to a 9.99% beneficial ownership blocker and the percentage set forth on row (11) and the number of shares of Common Stock set forth on rows (6), (8) and (9) give effect to such blocker.

     
     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is NovaBay Pharmaceuticals, Inc., a Delaware corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Hudson Bay Capital Management LP (the "Investment Manager") and Mr. Sander Gerber ("Mr. Gerber"), who are collectively referred to herein as "Reporting Persons."

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 28 Havemeyer Place, 2nd Floor, Greenwich, Connecticut 06830.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Gerber is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.01 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      66987P300

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

     
     

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentages used in this Schedule 13G are calculated based upon 2,035,444 shares of Common Stock outstanding as of December 22, 2022, as reported in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on December 30, 2022.  The percentage set forth on row (11) and the number of shares of Common Stock set forth on rows (6), (8) and (9) of the cover page for each Reporting Person are based on the Company's total number of outstanding shares of Common Stock and assume the exercise of warrants and the conversion of shares of convertible preferred stock held by Hudson Bay Master Fund Ltd. (collectively, the "Securities"), subject to the 9.99% Blocker (as defined below).
       
      Pursuant to the terms of the Securities, the Reporting Persons cannot exercise or convert such Securities if the Reporting Persons would beneficially own, after such exercise or conversion, more than 9.99% of the outstanding shares of Common Stock (the "9.99% Blocker").  The percentage set forth on Row (11) and the number of shares of Common Stock set forth on rows (6), (8) and (9) of the cover page for each Reporting Person give effect to the 9.99% Blocker.
       
      The Investment Manager serves as the investment manager to Hudson Bay Master Fund Ltd., in whose name the Securities are held. As such, the Investment Manager may be deemed to be the beneficial owner of all shares of Common Stock and the shares of Common Stock, subject to the 9.99% Blocker, if any, underlying the Securities held by Hudson Bay Master Fund Ltd. Mr. Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of the Investment Manager.  Mr. Gerber disclaims beneficial ownership of these securities.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
     
     

     

       
      See Item 4.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 10, 2023

     

    HUDSON BAY CAPITAL MANAGEMENT LP    
         
         
    By: /s/ Sander Gerber    
    Name: Sander Gerber    
    Title: Authorized Signatory    
         
         
    /s/ Sander Gerber    
    SANDER GERBER    

     

    Get the next $NBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:50:08 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:46:27 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:40:59 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

      Stockholders as of the March 18, 2025 record date will be entitled to vote Company engages financial advisor to explore strategic options should stockholders fail to approve the dissolution proposal NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Dissolution"). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission ("SEC") on F

      3/7/25 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

      Stockholders voted to unlock the value of NovaBay's Avenova® eyecare business by approving the $11.5 million asset sale Reconvened Special Meeting adjourned to allow additional time for votes to reach the 50% threshold of outstanding common stock in favor of Proposal Two, providing for the Dissolution of the Company Stockholders who have not yet voted are strongly encouraged to vote FOR Proposal Two at the Special Meeting scheduled to reconvene on January 30, 2025 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC ("PRN") for $11.

      1/23/25 8:00:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

      Reconvened meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and FOR Proposal Two at the Special Meeting to reconvene on January 16, 2025 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that its Reconvened Special Meeting of Stockholders held on December 18, 2024 has been adjourned until January 16, 2025 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares tha

      12/19/24 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    SEC Filings

    See more
    • NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

      4/22/25 5:02:17 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by NovaBay Pharmaceuticals Inc.

      10-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

      4/2/25 5:17:25 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by NovaBay Pharmaceuticals Inc.

      NT 10-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

      3/31/25 7:01:35 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

      SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

      11/8/24 5:31:40 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

      SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

      2/14/24 2:52:33 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

      SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

      2/13/24 5:17:39 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:50:08 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:46:27 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

      4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

      4/15/25 12:40:59 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Financials

    Live finance-specific insights

    See more
    • NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

      NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

      8/1/24 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

      Net product sales increased 13% over the prior year driven by higher sales of Avenova®-branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting continued digital marketing optimization Ordered product sales for Avenova-branded products on Amazon.com reached new all-time records in March and April Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. "Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products through online

      5/9/24 4:05:00 PM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

      NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:  Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

      5/3/24 6:50:00 AM ET
      $NBY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Innovations in Disinfection Technology Aid the Return of Workers

      NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

      12/9/20 9:00:00 AM ET
      $NBY
      $CEMI
      $BSGM
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Electromedical & Electrotherapeutic Apparatus